Health
Eli Lilly’s Stock Has Swung on Alzheimer’s Drug Developments. What Investors Need to Know. – Barron’s
Eli Lilly may have recently disappointed investors with a study’s data, but the approach being taken by it and other drugmakers to treat the disease seems to be…
When
Eli Lilly
presented the results of a small study of its Alzheimers disease therapy donanemab last weekend, investors were hoping for a miracle. It didnt materialize, and Lilly (ticker: LLY) shares, which had run up 11.7% when the company previewed the study back in January, slid 11.6% by the end of trading on Thursday.Those swings in the stock dont tell the real story of donanemab. The data that Lilly presented last Saturday were positive for Alzheimers drug development in general, and for…
-
General23 hours agoPolice say new leads being pursued after baby’s body found in Alexander Heights stormwater drain
-
Noosa News9 hours agoMan dies in Brisbane crash, women and girl rushed to hospital
-
Noosa News23 hours agoPolice charge second man over alleged assault in Gold Coast car seller on Facebook’s Marketplace
-
General19 hours agoSharp rise in airfares push UK inflation higher in July